Applying the New Guidelines of HER2 Testing in Breast Cancer
| Autor: | Ioana Moisini, Rana Ajabnoor, Huina Zhang, David G. Hicks, Bradley M. Turner |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Standardization Receptor ErbB-2 Breast Neoplasms Bone and Bones 03 medical and health sciences 0302 clinical medicine Breast cancer medicine Humans skin and connective tissue diseases Intensive care medicine Human Epidermal Growth Factor Receptor 2 Predictive biomarker Clinical Oncology business.industry Guideline medicine.disease 030104 developmental biology Oncology 030220 oncology & carcinogenesis Practice Guidelines as Topic Female Outcome data business |
| Zdroj: | Current oncology reports. 22(5) |
| ISSN: | 1534-6269 |
| Popis: | The human epidermal growth factor receptor 2 (HER2) is an important prognostic and predictive biomarker in the breast cancer. The American Society of Clinical Oncology/College of American Pathology (ASCO/CAP) has published HER2 testing guidelines in breast cancer. We herein reviewed the HER2 testing guidelines in breast cancer with a focus on the application of the current guidelines. The continual investigation of HER2 testing in breast cancer has resulted in updates in the HER2 testing guidelines. The current guidelines focus on the uncommon clinical scenarios and emphasize the coordination between immunohistochemistry and in situ hybridization results, in an effort to improve clarity and accuracy. The ASCO/CAP guidelines provide valuable recommendations to ensure the accurate evaluation of HER2 status in breast cancer patients through standardization. Additional studies, particularly those with long-term outcome data are still needed to validate the guideline recommendations, especially the uncommon cases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink